Lung cancer is the leading cause of cancer-related deaths in the world, and non-small-cell lung cancer (NSCLC) accounts for 80% of cases. MicroRNA-21 (miR-21) expression is increased and predicts poor survival in NSCLC. Although miR-21 function has been studied in vitro with cancer cell lines, the role of miR-21 in tumor development in vivo is unknown. We utilize transgenic mice with loss-of-function and gain-of-function miR-21 alleles combined with a model of NSCLC to determine the role of miR-21 in lung cancer. We show that overexpression of miR-21 enhances tumorigenesis and that genetic deletion of miR-21 partially protects against tumor formation. MiR-21 drives tumorigenesis through inhibition of negative regulators of the Ras/MEK/ERK pathway and inhibition of apoptosis.
INTRODUCTION
MicroRNAs are evolutionarily conserved, endogenous, nonprotein-coding, $20-23 nucleotide single-stranded RNAs that negatively regulate gene expression in a sequence-specific manner (Cho, 2007; Esquela-Kerscher and Slack, 2006; Voorhoeve and Agami, 2007) . The human genome is predicted to encode as many as 1000 miRNAs, or $3% of the total number of human genes (Bartel, 2004; Esquela-Kerscher and Slack, 2006) . The 5 0 portion of miRNA sequence containing bases two to eight, termed the ''seed'' region, is important in target mRNA recognition. miRNAs negatively regulate target gene expression through complementarity between the miRNA seed sequence and the target mRNA 3 0 untranslated region (UTR). miRNAs that bind with perfect complementarity to the protein encoding messenger RNA (mRNA) target the mRNA for destruction, whereas miRNAs with imperfect complementarity to the 3 0 UTR of the mRNA target repress mRNA translation. Expression of approximately 30% of human proteins appears to be regulated by miRNAs (Lewis et al., 2005) . Through interactions with 3 0 UTRs, miRNAs can modulate the expression of many genes simultaneously, often regulating individual signaling pathways at multiple levels (Baek et al., 2008; Selbach et al., 2008) .
An integral role of miRNAs in cancer pathogenesis has begun to emerge. miRNA expression profiling reveals characteristic signatures for many tumor types, including non-small-cell lung cancer (NSCLC) (Volinia et al., 2006) , and are predictive of tumor classification, prognosis, and response to therapy (Calin and Croce, 2006) . miRNA expression patterns are remarkably reliable markers of cancers; in some cases, they have even proven more reliable than conventional histology (Subramanian et al., 2008) . MicroRNAs are capable of functioning as classical tumor suppressors or oncogenes, thus actively participating
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in human cancer pathogenesis (Ventura and Jacks, 2009) . Recently, gain-and loss-of-function studies in mice demonstrate critical roles for miR-26a and miR-9 in hepatocellular carcinoma and breast cancer metastasis, respectively (Kota et al., 2009; Ma et al., 2010) . These data suggest that the pattern of miRNA expression contributes to fundamental aspects of tumor biology.
A large-scale survey to determine the miRNA signature of 540 tumor samples-including lung, breast, stomach, prostate, colon, and pancreatic tumors and their respective normal adjacent tissue-revealed miR-21 was the only miRNA upregulated in all these tumors (Volinia et al., 2006) . Further miRNA profiling in tumor samples and cancer cell lines showed increased miR-21 expression in glioblastoma (Chan et al., 2005; Ciafre et al., 2005) , head and neck carcinomas (Tran et al., 2007) , ovarian cancer (Iorio et al., 2007) , B cell lymphoma (Lawrie et al., 2007) , hepatocellular (Meng et al., 2007) , and cervical carcinoma (Lui et al., 2007) . These studies clearly illustrate miR-21 dysregulation in tumors; however, the studies do not prove a causal role for miR-21 in cancer pathogenesis.
Functional studies in cancer cell lines suggest that miR-21 has oncogenic activity. Knockdown of miR-21 in cultured glioblastoma cells activates caspases leading to apoptotic cell death, suggesting miR-21 is an antiapoptotic factor (Chan et al., 2005) . In breast cancer MCF-7 cells, miR-21 knockdown results in suppression of cell growth in vitro and tumor growth in xenografts (Si et al., 2007) . Knockdown of miR-21 in the metastatic breast cancer MD-MBA-231 cells reduced invasion and metastasis (Zhu et al., 2008) . Targeted deletion of miR-21 in RKO and DLD1 colon cancer cells revealed that miR-21 contributes to tumorigenesis through compromising cell cycle progression and DNA damage-induced checkpoint function through the CDC25A target gene . These studies indicate knockdown of miR-21 expression in cancer cell lines results in phenotypes important for tumor biology. However, the potential role of miR-21 in tumorigenesis in vivo has not yet been explored.
Lung cancer is the most common form of cancer in the world, accounting for approximately 12.3% of all cancers with an estimated 1.2 million new cases each year (Parkin et al., 2001 ). Lung cancer is also the leading cause of cancer-related deaths in the world, with NSCLC accounting for 80% of all cases (Ramalingam et al., 1998) . Despite novel therapies and advances in early detection, NSCLC is often diagnosed at an advanced stage and has a poor prognosis, with a median survival of 8 to 11 months and a 5 year survival rate in patients with NSCLC of only 13% using conventional cytotoxic chemotherapy (Soon et al., 2009) . Recently, miR-21 expression levels have proven useful prognostic markers in NSCLC (Markou et al., 2008; Yanaihara et al., 2006) . The level of miR-21 expression in sputum distinguishes patients with NSCLC from cancer-free control subjects with a greater sensitivity than conventional cytology (Xie et al., 2010) . Currently, more experiments are needed to determine whether miR-21 participates in driving the malignant phenotype or simply reflects the cellular stress.
In the current study, we used transgenic mice with both lossof-function and gain-of-function miR-21 alleles in combination with the K-ras LA2 mouse model of NSCLC to elucidate the role of miR-21 in NSCLC pathogenesis.
RESULTS

miR-21 Overexpression Promotes Tumor Development In Vivo
Increased expression of miR-21 in human cancer could reflect malignant physiology or could determine important aspects of cancer biology. To address this question, we generated transgenic mice that overexpress the miR-21 gene and mice with deletion of the miR-21 gene and tested the consequences in a mouse model of NSCLC. We designed a strategy to conditionally overexpress miR-21 using the Cre-lox system and the CAG-Z-EGFP vector (see Figure S1A and Supplemental Experimental Procedures available online) (Fukuda et al., 2005) . Global miR-21 overexpression was achieved by breeding the CAG-Z-miR21-EGFP mouse to transgenic mice expressing Cre recombinase from the ubiquitous CAG promoter resulting in the CAGmiR-21 mouse, which globally overexpressed miR-21 4-to 6-fold over normal levels of expression (Figures S1B-S1D). CAG-miR-21 transgenic mice were viable, fertile, and born in expected Mendelian ratios. miR-21 expression increases in mouse models of cardiac hypertrophy and following myocardial infarction; however, adult male CAG-miR-21 mice showed no signs of heart failure compared to littermate controls (Figure S1E) (van Rooij et al., 2006; van Rooij et al., 2008) .
To explore the role of miR-21 in the pathogenesis of NSCLC, we utilized the K-ras LA2 murine lung cancer model, which harbors a targeted, latent K-ras G12D allele that is activated by two distinct recombination events (Johnson et al., 2001 ). The first occurs in ES cells, and the second occurs in vivo, resulting in the random activation of the mutant K-ras G12D allele in somatic cells. K-ras LA2 mice develop multifocal lung tumors with 100% penetrance, and less frequently develop thymic lymphomas and skin papillomas (Johnson et al., 2001 Figure 1D ) and microscopically on H&E cross-section over all time points ( Figure 1F ). Total tumor area as a proportion of total lung area was significantly increased with miR-21 overexpression ( Figure 1E ). control mice ( Figure 1H ). This may be explained by a decreased incidence of thymic tumors in CAG-miR-21;K-ras LA2 mutant mice compared to K-ras LA2 controls ( Figure 1I ), thus contributing to the enhanced survival. Unlike K-ras LA1 ;p53 À/À compound mutant mice (Johnson et al., 2001 ), we did not observe an increased tumor spectrum or increased metastasis in the CAGmiR-21;K-ras LA2 mutant mice. miR-21 overexpression increased the incidence of all tumor grades without increasing the rate of conversion to adenocarcinoma, suggesting that miR-21 participates in tumor promotion rather than progression and metastasis in this model ( Figures 1J and 1K ). miR-21 overexpression did not increase the rate of recombination of the K-ras LA2 allele ( Figure S1F ). We followed CAG-miR-21 mice (n = 39) without K-ras LA2 for up to 555 days and performed full necropsy and histological analysis on H&E sections of the following tissues: lung, heart, brain, spleen, liver, kidney, stomach, colon, skeletal muscle, and bone marrow. No tumors were observed in CAGmiR-21 mice without K-ras
LA2
, indicating that miR-21 overexpression alone is not sufficient for tumorigenesis. These data suggest that miR-21 overexpression in human tumors does not simply reflect cancer pathology, but instead enhances aspects of the pathology of NSCLC.
miR-21 Deletion Suppresses Ras-Driven Transformation In Vitro
To address the necessity of miR-21 in the development of NSCLC, we generated miR-21 knockout mice. Homozygous miR-21 knock-out mice are viable, fertile, and born in expected Mendelian ratios without any gross phenotypic differences compared to wild-type or heterozygous littermates, and without a cardiac phenotype (D.P., E.V.R., and E.N.O., unpublished data). To dissect the role of miR-21 in Ras-driven transformation, we isolated mouse embryonic fibroblasts (MEFs) from wildtype and miR-21 À/À mice. Northern blot analysis and real-time PCR confirmed deletion of miR-21 ( Figures S2A and S2B ). These MEFs were immortalized and transformed with retroviruses expressing SV40 large T and small t antigens and H-ras G12V . There was no difference in proliferation between the miR-21 À/À and wild-type MEFs ( Figure S2C ). However, the miR-21 À/À MEFs formed significantly less colonies in soft agar than wild-type MEFs ( Figure S2D ) and developed smaller tumors in xenografts in nude mice ( Figure S2E ). These observations suggest that miR-21 actively participates in Ras-driven transformation.
miR-21 Deletion Suppresses Tumor Development In Vivo
Given that high levels of miR-21 expression in patients with NSCLC serve as an independent negative prognostic factor and that miR-21-deficient MEFs form fewer colonies in soft agar, we hypothesized that genetic deletion of miR-21 in the K-ras LA2 model would alter tumorigenesis. To explore this possibility, we crossed the miR-21 À/À allele into the K-ras LA2 NSCLC model. Significantly fewer tumors were present on the surface of the lungs of 20-week-old miR-21
Total tumor area as a proportion of total lung area was significantly decreased with miR-21 deletion ( Figure 2D ). miR-21 deletion did not alter proliferation in tumors measured by Ki67 staining ( Figure 2E ). miR21
;K-ras LA2 mice all develop lung tumors, but show an increased incidence of thymic lymphoma ( Figure 2F ). miR-21 À/À ;K-ras LA2 mutant mice displayed a reduced incidence of hyperplasic lesions and adenomas compared to K-ras LA2 controls ( Figure 2G ). Although not statistically significant, there was a trend toward decreased conversion of hyperplasia to adenoma in the miR-21 
miR-21 Targets Multiple Tumor Suppressor Genes
To identify miR-21 effectors responsible for phenotypes observed, we utilized two algorithms that predict the mRNA targets of miRNAs, TargetScan (Grimson et al., 2007) , and PicTar (Krek et al., 2005) . Approximately 180 mRNAs are predicted as miR-21 target genes on the basis of the presence of miR-21 sites in their 3 0 UTRs. Many of the miR-21-predicted targets have been reported to function as tumor suppressors and have been validated in vitro in previous studies (Selcuklu et al., 2009 ). We cloned the 3 0 UTRs of 24 putative mouse miR-21 target genes into a luciferase reporter construct. Reporter assays in COS cells revealed miR-21-dependent repression of 13 of the 24 3 0 UTRs, and mutation of the miR-21 site in the 3 0 UTR abrogated the repression in 11 of the putative target gene 3 0 UTRs ( Figure 3A) . Four of the validated miR-21 target genes are known negative regulators of the Ras/MEK/ERK pathway: sprouty 1 (Spry1), sprouty 2 (Spry2), B cell translocation gene 2 (Btg2), and programmed cell death 4 (Pdcd4). Several proapoptotic genes were directly targeted by miR-21, apoptotic peptidase activating factor 1 (Apaf1), Fas ligand (Faslg), Pdcd4, and ras homolog gene family member B (RhoB). We show miR-21-dependent repression of the mouse Apaf1 3 0 UTR reporter; however, the miR-21 site in the human APAF1 3 0 UTR is conserved in primates but not conserved in the mouse. Eleven of the putative miR-21 target gene 3 0 UTRs, including phosphatase and tensin homolog (Pten), were not repressed by miR-21 ( Figure 3B ). Caspase 3 and K-ras do not contain miR-21 sites in their 3 0 UTR, and the 3 0 UTR luciferase reporter activity is not suppressed by miR-21 (Figure 3B) . These results suggest that in vitro miR-21 can repress multiple tumor suppressor genes that may participate in tumorigenesis.
Oncogenic Ras Activation Increases miR-21 Expression In Vivo
Previously, an autoregulatory loop connecting miR-21 and Ras activation through AP-1 was illustrated in a rat thyroid cell system (Talotta et al., 2009) . miR-21 expression was induced by AP-1 in response to Ras activation, and miR-21 mediated Ras-dependent downregulation of Pdcd4 (Talotta et al., 2009 ), a known negative regulator of AP-1 transactivation (Goke et al., 2004; Jansen et al., 2005; Yang et al., 2003; Yang et al., 2001 ). In addition, epidermal growth factor receptor (EGFR) and HER2/neu signaling positively regulates miR-21 expression in human lung and breast carcinoma cell lines, respectively (Huang et al., 2009; Seike et al., 2009 expression was more than additive compared to either CAGmiR-21 or K-ras LA2 mice alone. We speculate that, by driving miR-21 expression in the transgenic mouse, we provided a ''second hit'' prior to K-ras activation, thus accelerating tumor initiation.
miR-21 Targets Multiple Negative Regulators of Ras Signaling
Multiple negative regulators of the Ras/MEK/ERK pathway were shown to be direct miR-21 target genes by luciferase reporter assays ( Figure 3B ). Although there have been reports of miR-21 target gene regulation in cancer cell lines, the constellation of genes regulated by miR-21 in NSCLC in vivo remains elusive. We hypothesize that increased miR-21 expression potentiates Ras signaling through inhibition of antagonists of the Ras pathway, such as Spry1, Spry2, Btg2, and Pdcd4 (Casci et al., 1999; Hanafusa et al., 2002; Lo et al., 2006) .
We isolated individual tumors from mice, made whole tumor lysates, and performed western blots for putative miR-21 targets to address the effect of miR-21 expression on the protein levels of the miR-21 target genes in vivo within lung tumors. miR-21 overexpression in CAG-miR-21;K-ras LA2 mutant tumors decreases Spry1, Spry2, and Btg2 protein expression compared to K-ras LA2 tumors ( Figure 4C ). The decrease in Spry1, Spry2, and Btg2 in CAG-miR-21;K-ras LA2 tumors correlates with increased Ras pathway activity, shown by increased ERK phosphorylation ( Figure 4C ). miR-21 À/À ;K-ras LA2 mutant tumors did not show alteration in the regulation of ERK by Spry1, Spry2, and Btg2 ( Figure 4D ). Protein analysis of individually isolated tumors showed that Pdcd4 levels were decreased in CAGmiR-21;K-ras LA2 compound mutant mice compared to K-ras LA2 control tumors ( Figure 4C ). This regulation was absent in tumors from the miR-21
;K-ras LA2 compound mutant mice (Figure 4D) . RECK, Cdc25a, Map2k3, NfiB, Trp63, and Ski have been shown to be miR-21 target genes in vitro, but only RECK showed decreased protein levels in the CAG-miR-21;K-ras LA2 tumors ( Figure S3A ). phosphorylation ( Figure S3B ). These data show that miR-21 overexpression decreases the protein expression of four miR-21 target genes that are tumor suppressors and negative regulators of the Ras/MEK/ERK pathway, resulting in a concomitant increased ERK activity. and 5B). Deletion of miR-21 had no effect on the amount of apoptosis in the lung lesions, as detected by TUNEL, suggesting that lung tumors that develop in the background of the genetic deletion of miR-21 have escaped miR-21 regulatory effects ( Figure 5C ). Several miR-21 target genes are tumor suppressors involved in apoptosis, including Apaf11, Pdcd4, RhoB, and Faslg. Lysates from individually isolated tumors from CAG-miR-21;K-ras LA2 mice showed Figure 5E ). Apaf1, Pdcd4, Faslg, and RhoB were validated as direct miR-21 target genes by luciferase reporter assays; however, caspase 3 was not directly regulated by miR-21 ( Figure 3B ). Quantification of miR-21 target Western blots is shown in Figure 5F . These data illustrate that miR-21 overexpression decreases the protein expression of four miR-21 target genes that are involved in apoptosis thus promoting survival.
miR-21 Deletion Sensitizes Cells to DNA-Damaging Chemotherapy
Recent studies illustrate that miRNAs modulate sensitivity of cells to chemotherapy (Blower et al., 2008) . We utilized the miR-21 À/À and wild-type MEFs immortalized with TAg and transformed with RasV12 to test the role of miR-21 in doxorubicininduced apoptosis. MEFs were cultured with increasing concentrations of doxorubicin, whole cell lysates were isolated, and apoptotic activity was measured by immunoblotting for cleaved caspase 3. MEFs from miR-21 À/À mice display increased sensitivity to doxorubicin-induced apoptosis measured by protein levels of cleaved caspase 3 ( Figure 6A ). miR-21 À/À MEFs were transduced with a lentivirus expressing miR-21 to rescue the miR-21 deficiency ( Figure S4 ). Lentiviral overexpression of miR-21 decreased cleaved caspase 3 levels compared to empty lentiviral transduced miR-21 À/À MEFs. The increased sensitivity to doxorubicin-induced apoptosis measured by cleaved caspase 3 levels was confirmed by TUNEL ( Figure 6C ). Therefore, miR-21 plays a significant role in inhibition of apoptosis thus allowing tumor survival.
DISCUSSION
Our results show that miR-21 expression modulates tumor number, incidence, and size in a mouse lung cancer model initiated by oncogenic K-ras
G12D
, consistent with miR-21 functioning as a tumor promoter. miR-21 was not sufficient in our model for tumorigenesis; however, under the control of other tissue-specific promoters, miR-21 could have cancer related phenotypes. miR-21 modulates several components critical to NSCLC pathogenesis through both relieving antagonism of the Ras pathway and reducing apoptotic effectors (Figure 7) . Although we show regulation of protein levels of miR-21 target genes with miR-21 overexpression, we do not observe robust changes in protein levels on miR-21 target genes with miR-21 deletion, suggesting that miR-21 may act through additional mechanisms. By targeting antagonists of Ras/MEK/ERK signaling and proapoptotic genes, miR-21 enhances tumor proliferation and survival, two critical components of tumor promotion. Figure 4C , Figure 5D , and Figures Our results define in vivo an autoregulatory loop between oncogenic Ras and miR-21 mediated by Spry1, Spry2, Btg2, and Pdcd4. PDCD4 is a proapoptotic tumor suppressor gene and has been verified as a miR-21 target in human colorectal and breast cancer cell lines (Afonja et al., 2004; Asangani et al., 2008; Bitomsky et al., 2008; Frankel et al., 2008; Lu et al., 2008; Zhang et al., 2006) . Pdcd4 functions both as an inducer of apoptosis and a suppressor of AP-1 activity (Hwang et al., 2007) . Loss of PDCD4 expression in human lung cancer correlates with higher grade and disease stage (Chen et al., 2003) . MiR-21 targets SPRY2 in cardiomyocytes and SW480 colon cancer cells, enhancing cell migration (Sayed et al., 2008) . SPRY2, in turn, negatively regulates Ras/MEK/ERK signaling and is a tumor suppressor in NSCLC in both mice (Minowada and Miller, 2004; Minowada and Miller, 2009; Shaw et al., 2007) and humans (Sutterluty et al., 2007) . In laryngeal carcinoma, miR-21 targets BTG2 (Liu et al., 2009 ), a p53 target gene, recently shown to suppress oncogenic Ras activity by reducing the GTP-bound, active state (Buganim et al., 2010) . Although the reductions in protein levels of individual miR-21 targets appear modest with miR-21 overexpression, collectively this diminution of tumor suppressor activity allows for more robust tumor formation through relieving multiple nodes of inhibition of the Ras/MEK/ ERK pathway, thus facilitating tumor proliferation.
Oncogenic Ras activation has been shown to increase the expression of Spry2, providing feedback inhibition of Ras activation (Shaw et al., 2007) . We show that Ras activation increases miR-21 expression and, in turn, decreases the expression of Spry2. The genetic deletion of miR-21 removes the miR-21 mediated downregulation of Spry2, resulting in more Spry2-mediated Ras/MEK/ERK inhibition and tumor suppressor activity. We postulate that the tumors formed in the background of miR-21 deletion have developed escape mechanisms to circumvent the Spry2 tumor suppressor activity. The necessity to circumvent the lack of miR-21 protumorigenic effects could explain the latency of tumor formation in the miR-21 À/À mice.
Previous work in cancer cell lines has implicated miR-21 as a suppressor of apoptosis. Knock-down of miR-21 in glioblastoma cell lines triggers the activation of caspases and increases
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Role of MicroRNA-21 in Lung Tumor Pathogenesis apoptosis (Chan et al., 2005) . Zhang et al. (2008) showed in a human gastric cancer cell line that forced overexpression of miR-21 enhanced tumor proliferation and invasion and knockdown of miR-21 resulted in a marked reduction in proliferation and increase in apoptosis. The present work illustrates in vivo that increased expression of miR-21 significantly reduces apoptosis in mouse lung tumors. MiR-21 overexpression resulted in reduced protein levels of Apaf1, a key component of the intrinsic, mitochondrial apoptotic pathway, as well as decreased expression of Faslg, a key initiator of the extrinsic, death receptor apoptotic pathway. Faslg mRNA is expressed in human lung tumors; however, the Faslg protein is only detected in a small fraction of lung tumors (Badillo-Almaraz et al., 2003) . miR-21-mediated translational inhibition could partially explain this finding. Overexpression of miR-21 correlated with a decrease RhoB protein levels. RhoB promotes growth inhibition and induces apoptosis in cancer cells (Kim et al., 2009) , and RhoB expression is downregulated in human NSCLC, suggesting a role as a tumor suppressor gene (Sato et al., 2007) . Relieving miR-21 inhibition of proapoptotic genes could provide a means to augment the effect of current chemotherapy.
Methods have been developed to manipulate miRNA function pharmacologically, facilitating the development of new cancer therapeutic strategies (Hutvagner et al., 2004; Krutzfeldt et al., 2005) . Increased sensitivity to DNA-damaging agents in the miR-21 mice were observed daily from birth and were sacrificed at the first sign of shortness of breath, reduced locomotion, or reduced body weight (>20% of total body weight).
RNA Purification, RT-PCR, and Real-Time PCR Total RNA was isolated from normal lung or lung tumors with Trizol reagent (Invitrogen) according to the manufacturer's protocol. miRNA levels were determined by Northern blot analysis and real-time PCR. RT-PCR was performed using the TaqMan microRNA reverse-transcriptase kit (Applied Biosystems). Real-time PCR was performed using TaqMan probes on an ABI-PE Prism 7000 sequence detection system according to the manufacturer's protocol. The relative quantities of miRNA were determined using the CT method and were normalized to RNU6B. The recombination of the K-ras LA2 allele was determined by RT-PCR. Total RNA was isolated from microdissected normal lung and lung tumors. Reverse transcription was performed using random hexamer primers and SuperScript III First-Strand Synthesis (Invitrogen). PCR primers used and conditions were previously described (Johnson et al., 2001 ).
Northern Blot Analysis
Ten micrograms of total RNA from different tissues or tumors was resolved on a 20% polyacrylamide (7.6 M urea) gel in 13 TBE. RNA was then transferred onto a Zetaprobe GT membrane (Bio-Rad) in 0.53 TBE buffer at 80 V for 1 hr. Hybridization was performed at 39 C. 32 P-labeled Star-Fire oligonucleotide probes (IDT) against the mature miR-21 and U6 were used in hybridization. U6 was used as a loading control.
Histology, Immunohistochemistry, and TUNEL For determining tumor incidence and grade, whole lungs were manually inflated with 10% neutral-buffered formalin, placed in fixative for 3 days, embedded in paraffin, and sectioned at the level of the tracheal bifurcation at 5 mm intervals. H&E stains were performed using standard procedures. Lung and tumor areas were determined using ImageJ software. Tumor burden was expressed as the sum of the tumor area divided by the total lung area. Proliferation was assessed by immunohistochemistry using antibodies against Ki67 (Abcam). Paraffin-embedded sections were deparaffinized, heated in a microwave in 0.01 M sodium citrate buffer for antigen retrieval, treated with 3% H 2 O 2 for 10 min, and rinsed in H 2 O and PBS. Sections were blocked in 5% goat serum in PBS followed incubation with anti-Ki67 antibody (Abcam). Signals were detected with Vectastain ABC kit (Vector Laboratories) and 3,3 0 -diaminobenzidine (DAB) substrate (Vector Laboratories). Sections were counterstained with hematoxylin and mounted. Ki67 positive cells were scored per high-power field from three separate animals (four tumors per animal), and each genotype and represented as the mean percentage of the total number of cells ± SEM. Apoptosis was evaluated by staining paraffin sections with In situ cell death detection kit, TMR red terminal deoxynucleotidyl-transferasemediated dUTP nick-end labeling (TUNEL) system (Roche) according to the manufacturer's protocol. Slides were mounted with Vectashield mounting medium with DAPI (Vector Laboratories). The number of apoptotic cells per lung tumor were recorded and presented as the mean ± SEM.
Tumor Grading
All tumors from the survival cohort were analyzed on H&E sections and categorized as hyperplasia, atypical adenomatous hyperplasia, adenoma, adenoma with typia, and adenocarcinoma, according to the Mouse Models of Human Cancer Consortium recommendations (Nikitin et al., 2004) .
Western Blot Analysis
Individual tumors were microdissected from the lungs and snap frozen in liquid nitrogen. Individual tumor and lung lysates were prepared in RIPA with protease inhibitors (Roche complete mini) and phosphatase inhibitor cocktail (Sigma) using a manual pestle homogenizer and clarified by centrifugation at 12,000 g for 10 min at 4 C. Protein concentration was determined by BCA assay (Themo Scientific), and equivalent amounts were resolved by SDS-PAGE and immunoblotted by a standard protocol. Antibodies were purchased from Abcam (Spry1, Spry2, Btg2, NfiB, Ski, and Trp63), Cell Signaling (phosphor-ERK, total ERK, total Caspase 3, Apaf1, RhoB, PTEN, PIK3R1, phosphor-Akt(Ser473), total Akt, RECK, Cdc25a, and Map2k3), Chemicon (GAPDH and Faslg), and Rockland (Pdcd4). Quantification of Western blots was performed by densitometry using NIH ImageJ software. Each sample was normalized to GAPDH and represented as a fraction of K-ras LA2 control tumors.
Reporter Assays
The 466 base-pair genomic fragment encompassing miR-21 was amplified by PCR and ligated into pCMV6. Full-length 3 0 UTRs of putative miR-21 target genes were cloned from mouse 129SvEv genomic DNA and subcloned into the pMiR-report vector (Ambion). Mutations in the putative miR-21 site in the 3 0 UTRs were generated by QuickChange mutagenesis (Stratagene) to alter the second and third nucleotides of the targeting sequence. Cell culture, transfection, and luciferase reporter assays were performed as previously described (van Rooij et al., 2008).
Doxorubicin-Induced Apoptosis
Wild-type and miR-21 À/À MEFs immortalized with T-Ag and transformed with H-ras V12 were seeded in a 6-well plate at 1 3 10 5 cells per well. Cells were treated with vehicle control and increasing doxorubicin concentrations from 100 nM to 10 mM for 12 hr. Cells were lysed in RIPA, and protein concentrations were determined by BCA (Thermo Scientific). Western blotting of 50 mg of lysates was performed with antibodies directed against pro-and cleaved Caspase 3 (Cell Signaling) and GAPDH (Chemicon). Quantification of Western blots was performed by densitometry using NIH ImageJ software. Cleaved caspase 3 levels were expressed as a ratio of pro-caspase 3 and were normalized to either WT untreated or empty vector untreated samples. For TUNEL assays, MEFs were seeded in a 6-well plate at 1 3 10 5 cells per well on coverslips. Cells were treated with vehicle control or 1 mM doxorubicin for 12 hr. TUNEL was performed using an in situ cell death detection kit, TMR red terminal deoxynucleotidyl-transferase-mediated dUTP nick-end labeling (TUNEL) system (Roche) according to manufacturer's protocol.
Statistical Analysis
Results are expressed as the mean ± SEM. We utilized a two-tailed, unpaired Student's t test for all pair-wise comparisons (GraphPad Prism version 5). p values less than 0.05 were considered significant.
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